These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30786890)

  • 1. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
    Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
    Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
    Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
    Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
    Yallowitz A; Ghaleb A; Garcia L; Alexandrova EM; Marchenko N
    Cell Death Dis; 2018 May; 9(6):621. PubMed ID: 29799521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
    Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
    Kennedy SP; Han JZR; Portman N; Nobis M; Hastings JF; Murphy KJ; Latham SL; Cadell AL; Miladinovic D; Marriott GR; O'Donnell YEI; Shearer RF; Williams JT; Munoz AG; Cox TR; Watkins DN; Saunders DN; Timpson P; Lim E; Kolch W; Croucher DR
    Breast Cancer Res; 2019 Mar; 21(1):43. PubMed ID: 30898150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
    Yang ZY; Yang L; Xu CW; Wang XJ; Lei L
    Biol Open; 2020 Jan; 9(1):. PubMed ID: 31980423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.
    Wolfson E; Solomon S; Schmukler E; Goldshmit Y; Pinkas-Kramarski R
    Cell Death Dis; 2018 Jan; 9(2):47. PubMed ID: 29352243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-metastasis activity of black rice anthocyanins against breast cancer: analyses using an ErbB2 positive breast cancer cell line and tumoral xenograft model.
    Luo LP; Han B; Yu XP; Chen XY; Zhou J; Chen W; Zhu YF; Peng XL; Zou Q; Li SY
    Asian Pac J Cancer Prev; 2014; 15(15):6219-25. PubMed ID: 25124601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
    Li D; Marchenko ND
    Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
    Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
    J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.
    Jeong J; Choi J; Kim W; Dann P; Takyar F; Gefter JV; Friedman PA; Wysolmerski JJ
    J Biol Chem; 2019 Jan; 294(3):887-901. PubMed ID: 30463939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
    Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
    Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.